Journal article
Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids
Clinical pharmacology and therapeutics, Vol.99(1), pp.59-71
01/2016
DOI: 10.1002/cpt.281
PMID: 26492546
Abstract
Statins are established therapies for cardiovascular disease prevention and ezetimibe has recently been shown to modestly reduce cardiovascular events when added to background statin therapy. Yet here remains a clear unmet need for additional therapies aimed at lowering low density lipoprotein cholesterol (LDL-C) to further reduce cardiovascular risk. Multiple strategies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition have emerged as effective modalities for LDL-C lowering. PCSK9 monoclonal antibodies are the farthest along in clinical development and alirocumab and evolocumab were approved for clinical use by regulatory agencies in 2015. In addition to robust LDL-C lowering (nearly 50-65% from baseline), they improve other lipid parameters as well. Adverse events associated with these medications are minimal. Importantly, they improve clinical cardiovascular disease outcomes, although long-term study results are awaited. Cost may be an important limiting factor in their use and we propose two possible solutions which can potentially curtail cost.
Details
- Title: Subtitle
- Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids
- Creators
- G P S Shantha - Departments of Epidemiology & Medicine, Prevention Intervention Center, Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa, USAJ G Robinson - Departments of Epidemiology & Medicine, Prevention Intervention Center, Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa, USA
- Resource Type
- Journal article
- Publication Details
- Clinical pharmacology and therapeutics, Vol.99(1), pp.59-71
- Publisher
- United States
- DOI
- 10.1002/cpt.281
- PMID
- 26492546
- ISSN
- 0009-9236
- eISSN
- 1532-6535
- Language
- English
- Date published
- 01/2016
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center; Internal Medicine
- Record Identifier
- 9983996060702771
Metrics
25 Record Views